Covaris, Inc. Signs Co-Marketing Agreement with Illumina, Inc. (ILMN) to Combine Next-Gen Sequencing Platforms with Controlled DNA Shearing
9/28/2010 9:56:25 AM
WOBURN, Mass., Sept. 28 /PRNewswire/ -- Covaris Inc. (a privately-held MA based company) today announced that it has signed a co-marketing agreement with Illumina, Inc. (Nasdaq: ILMN) making Covaris DNA shearing technologies the recommended method of shearing with Illumina next-generation sequencing product lines, including HiSeq, HiScanSQ, and Genome Analyzer. In addition, the proprietary Covaris process enables higher recoveries for nucleic acid extraction, tissue homogenization, chromatin shearing, protein digestion, and cell lysis. The highly controlled Covaris technology is isothermal and non-contact, ensuring molecular stability throughout the sample preparation process. Important for next-generation genetic analysis, the Covaris system allows customers to rapidly and precisely scale up sample processing capability. The Illumina-Covaris partnership will bring industry leading next-generation DNA shearing performance to Illumina's sequencing customers.
About Covaris, Inc.
Covaris, Inc. provides advanced sample preparation systems for life and analytical science. Our sample prep technologies support a wide variety of applications including next-generation DNA sequencing, ChIP, proteomics, and compound management. Our patented Adaptive Focused Acoustic (AFA) technology enables a high energy density to bring unsurpassed speed and efficiency to biological and chemical sample preparation. The AFA process, based on shock wave physics, delivers controlled, precise, and accurate energy to biological and chemical samples. Information about Covaris is available at www.covarisinc.com.
SOURCE Covaris, Inc.